293 related articles for article (PubMed ID: 31431620)
1. Integrative and comparative genomic analyses identify clinically relevant pulmonary carcinoid groups and unveil the supra-carcinoids.
Alcala N; Leblay N; Gabriel AAG; Mangiante L; Hervas D; Giffon T; Sertier AS; Ferrari A; Derks J; Ghantous A; Delhomme TM; Chabrier A; Cuenin C; Abedi-Ardekani B; Boland A; Olaso R; Meyer V; Altmuller J; Le Calvez-Kelm F; Durand G; Voegele C; Boyault S; Moonen L; Lemaitre N; Lorimier P; Toffart AC; Soltermann A; Clement JH; Saenger J; Field JK; Brevet M; Blanc-Fournier C; Galateau-Salle F; Le Stang N; Russell PA; Wright G; Sozzi G; Pastorino U; Lacomme S; Vignaud JM; Hofman V; Hofman P; Brustugun OT; Lund-Iversen M; Thomas de Montpreville V; Muscarella LA; Graziano P; Popper H; Stojsic J; Deleuze JF; Herceg Z; Viari A; Nuernberg P; Pelosi G; Dingemans AMC; Milione M; Roz L; Brcic L; Volante M; Papotti MG; Caux C; Sandoval J; Hernandez-Vargas H; Brambilla E; Speel EJM; Girard N; Lantuejoul S; McKay JD; Foll M; Fernandez-Cuesta L
Nat Commun; 2019 Aug; 10(1):3407. PubMed ID: 31431620
[TBL] [Abstract][Full Text] [Related]
2. Identification of deregulation of apoptosis and cell cycle in neuroendocrine tumors of the lung via NanoString nCounter expression analysis.
Walter RF; Werner R; Ting S; Vollbrecht C; Theegarten D; Christoph DC; Schmid KW; Wohlschlaeger J; Mairinger FD
Oncotarget; 2015 Sep; 6(28):24690-8. PubMed ID: 26008974
[TBL] [Abstract][Full Text] [Related]
3. An in-silico analysis reveals further evidence of an aggressive subset of lung carcinoids sharing molecular features of high-grade neuroendocrine neoplasms.
Pelosi G; Melocchi V; Dama E; Hofman P; De Luca M; Albini A; Gemelli M; Ricotta R; Papotti M; La Rosa S; Uccella S; Harari S; Sonzogni A; Asiedu MK; Wigle DA; Bianchi F
Exp Mol Pathol; 2024 Feb; 135():104882. PubMed ID: 38237798
[TBL] [Abstract][Full Text] [Related]
4. CD44 and OTP are strong prognostic markers for pulmonary carcinoids.
Swarts DR; Henfling ME; Van Neste L; van Suylen RJ; Dingemans AM; Dinjens WN; Haesevoets A; Rudelius M; Thunnissen E; Volante M; Van Criekinge W; van Engeland M; Ramaekers FC; Speel EJ
Clin Cancer Res; 2013 Apr; 19(8):2197-207. PubMed ID: 23444222
[TBL] [Abstract][Full Text] [Related]
5. Expression of delta-like protein 3 is reproducibly present in a subset of small cell lung carcinomas and pulmonary carcinoid tumors.
Xie H; Boland JM; Maleszewski JJ; Aubry MC; Yi ES; Jenkins SM; Koepplin JW; Terra SBSP; Mansfield AS; Roden AC
Lung Cancer; 2019 Sep; 135():73-79. PubMed ID: 31447005
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical analysis of OTP and NKX6.1 in neuroendocrine tumors of the lung and pancreas.
Yoxtheimer LM; Heymann JJ; Cohen C; Rao RA; Goyal A; Siddiqui MT
Diagn Cytopathol; 2018 Dec; 46(12):1010-1014. PubMed ID: 30284410
[TBL] [Abstract][Full Text] [Related]
7. Differential expression and prognostic value of the chemokine receptor CXCR4 in bronchopulmonary neuroendocrine neoplasms.
Kaemmerer D; Reimann C; Specht E; Wirtz RM; Sayeg M; Baum RP; Schulz S; Lupp A
Oncotarget; 2015 Feb; 6(5):3346-58. PubMed ID: 25671300
[TBL] [Abstract][Full Text] [Related]
8. Differential Orthopedia Homeobox expression in pulmonary carcinoids is associated with changes in DNA methylation.
Moonen L; Mangiante L; Leunissen DJG; Lap LMV; Gabriel A; Hillen LM; Roemen GM; Koch A; van Engeland M; Dingemans AC; Foll M; Alcala N; Fernandez-Cuesta L; Derks JL; Speel EM
Int J Cancer; 2022 Jun; 150(12):1987-1997. PubMed ID: 35076935
[TBL] [Abstract][Full Text] [Related]
9. Tumor characteristics, expressions of ERCC1, Bax, p53, IGF1R, Bcl2, Bcl2/Bax and prognostic factors for overall survival in patients with lung carcinoid.
Velinovic M; Jankovic R; Jovanovic D; Skodric Trifunovic V; Gavrilovic D; Stojsic J; Cavic M
J BUON; 2019; 24(1):256-266. PubMed ID: 30941978
[TBL] [Abstract][Full Text] [Related]
10. Proposal of a Panel of Genes Identified by miRNA Profiling as Candidate Prognostic Biomarkers in Lung Carcinoids.
Rapa I; Votta A; Giorcelli J; Izzo S; Rigutto A; Metovic J; Napoli F; Volante M
Neuroendocrinology; 2021; 111(1-2):115-122. PubMed ID: 32040954
[TBL] [Abstract][Full Text] [Related]
11. Malignancy-associated X chromosome allelic losses in foregut endocrine neoplasms: further evidence from lung tumors.
D'Adda T; Bottarelli L; Azzoni C; Pizzi S; Bongiovanni M; Papotti M; Pelosi G; Maisonneuve P; Antonetti T; Rindi G; Bordi C
Mod Pathol; 2005 Jun; 18(6):795-805. PubMed ID: 15578070
[TBL] [Abstract][Full Text] [Related]
12. Transcriptomic data helps refining classification of pulmonary carcinoid tumors with increased mitotic counts.
Sazonova O; Manem V; Orain M; Khoshkrood-Mansoori B; Gaudreault N; Desmeules P; Bossé Y; Joubert P
Mod Pathol; 2020 Sep; 33(9):1712-1721. PubMed ID: 32291397
[TBL] [Abstract][Full Text] [Related]
13. Molecular and cellular biology of neuroendocrine lung tumors: evidence for separate biological entities.
Swarts DR; Ramaekers FC; Speel EJ
Biochim Biophys Acta; 2012 Dec; 1826(2):255-71. PubMed ID: 22579738
[TBL] [Abstract][Full Text] [Related]
14. Orthopedia homeobox protein (OTP) is a sensitive and specific marker for primary pulmonary carcinoid tumors in cytologic and surgical specimens.
Viswanathan K; Borczuk AC; Siddiqui MT
J Am Soc Cytopathol; 2019; 8(1):39-46. PubMed ID: 30929758
[TBL] [Abstract][Full Text] [Related]
15. Folic-acid metabolism and DNA-repair phenotypes differ between neuroendocrine lung tumors and associate with aggressive subtypes, therapy resistance and outcome.
Walter RF; Mairinger FD; Werner R; Vollbrecht C; Hager T; Schmid KW; Wohlschlaeger J; Christoph DC
Oncotarget; 2016 Apr; 7(15):20166-79. PubMed ID: 27064343
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive Characterization of the Genomic Landscape in Chinese Pulmonary Neuroendocrine Tumors Reveals Prognostic and Therapeutic Markers (CSWOG-1901).
Peng W; Cao L; Chen L; Lin G; Zhu B; Hu X; Lin Y; Zhang S; Jiang M; Wang J; Li J; Li C; Shao L; Du H; Hou T; Chen Z; Xiang J; Pu X; Li J; Xu F; Loong H; Wu L
Oncologist; 2022 Mar; 27(2):e116-e125. PubMed ID: 35641209
[TBL] [Abstract][Full Text] [Related]
17. DLL3 expression in large cell neuroendocrine carcinoma (LCNEC) and association with molecular subtypes and neuroendocrine profile.
Hermans BCM; Derks JL; Thunnissen E; van Suylen RJ; den Bakker MA; Groen HJM; Smit EF; Damhuis RA; van den Broek EC; ; Ruland A; Speel EJM; Dingemans AMC
Lung Cancer; 2019 Dec; 138():102-108. PubMed ID: 31678831
[TBL] [Abstract][Full Text] [Related]
18. ERCC1 and Ki67 in small cell lung carcinoma and other neuroendocrine tumors of the lung: distribution and impact on survival.
Skov BG; Holm B; Erreboe A; Skov T; Mellemgaard A
J Thorac Oncol; 2010 Apr; 5(4):453-9. PubMed ID: 20104194
[TBL] [Abstract][Full Text] [Related]
19. Large cell neuroendocrine carcinoma of the lung: a histologic and immunohistochemical study of 22 cases.
Jiang SX; Kameya T; Shoji M; Dobashi Y; Shinada J; Yoshimura H
Am J Surg Pathol; 1998 May; 22(5):526-37. PubMed ID: 9591721
[TBL] [Abstract][Full Text] [Related]
20. MGMT promoter methylation and 1p/19q co-deletion of surgically resected pulmonary carcinoid and large-cell neuroendocrine carcinoma.
Lei L; Jiang Z; Zhang G; Cheng Q; Lu H
World J Surg Oncol; 2018 Jun; 16(1):110. PubMed ID: 29914531
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
